ABSTRACT Background: Cystic fibrosis (CF) is caused by compound heterozygosity or homozygosity of CF transmembrane conductance regulator gene (CFTR) mutations. Phenotypic variability associated with certain mutations makes genetic counselling difficult, notably for R117H, whose disease phenotype varies from asymptomatic to classical CF. The high frequency of R117H observed in CF newborn screening has also introduced diagnostic dilemmas. The aim of this study was to evaluate the disease penetrance for R117H in order to improve clinical practice. Methods: The phenotypes in all individuals identified in France as compound heterozygous for R117H and F508del, the most frequent CF mutation, were described. F508del] was estimated at 0.03% and that of severe CF in adulthood at 0.06%. Conclusions: These results suggest that R117H should be withdrawn from CF mutation panels used for screening programmes. The real impact of so-called disease mutations should be assessed before including them in newborn or preconceptional carrier screening programmes.
T Bienvenu, 9, 13 B Gérard, 9,14 P Boisseau, 9,15 F Cabet-Bey, 9 ,16 D Feldmann, 9,17 C Clavel, 9, 18 E Bieth, 9, 19 A Iron, 9, 20 B Simon-Bouy, 9 ,21 C Costa, 9,22 R Medina, 22 J Leclerc, 9, 11 D Hubert, 3, 23 R Nové-Josserand, 3, 24 I Sermet-Gaudelus, 3, 25 pancreatic insufficiency, male infertility and elevated sweat chloride concentrations. 1 Over 1500 sequence variations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene have been identified in CF and in a number of CFTR-related disorders (CFTR-RD).
2 CFTR-RD are defined as clinical entities where there is evidence of CFTR dysfunction but where the criteria for the diagnosis of CF are not met, 3 and mostly include isolated male infertility due to congenital bilateral absence of the vas deferens (CBAVD (MIM 277180), 4 disseminated bronchiectasis 5 6 and chronic pancreatitis. 7 8 CFTR mutations have diverse effects on CFTR protein expression and function. 9 The wide phenotypic spectrum associated with some genotypes, probably influenced by environmental and modifying genetic factors, 3 complicates genetic counselling.
The R117H mutation was initially considered as a mutation causing mild CF with pancreatic sufficiency, 10 in keeping with a residual CFTR function supported by in vitro studies.
11 R117H was then considered as predominantly associated with isolated CBAVD, 4 12-14 generally in compound heterozygosity with F508del, the most frequent CF mutation. Incidentally, the [R117H]+[F508del] genotype was observed in asymptomatic individuals. 15 Phenotypic variability was mostly attributed to the presence of a polypyrimidine variant in the intron 8 acceptor splice site (T5 or T7) in cis with R117H, leading to R117H;T5 or R117H;T7 alleles. While the T7 variant is considered neutral, the T5 variant was shown to affect exon 9 splicing reducing the amount of CFTR protein, probably causing a more severe phenotype. 15 16 It was therefore suggested to consider R117H as a CF mutation only in the context of the R117;T5 complex allele. 17 However, early pulmonary manifestations were reported in patients carrying a severe CF mutation and R117H;T7. 16 18-20 The implementation of systematic CF newborn screening (CFNBS) since 2002 in France, relying on determination of immunoreactive trypsinemia (IRT) and subsequent screening for 30 common CFTR mutations when IRT is above 65 mg/l, led to observe a much higher frequency of R117H;T7 in this population than in CF patients, 21 adding further to the diagnostic dilemma. 16 21-24 To assist with genetic counselling and to improve diagnostic practice, we implemented a large collaborative study to: (1) 
RESULTS

Phenotypic description of patients compound heterozygous for R117H and F508del
Among 278 All individuals were living, apart from one non-NBS patient, who died of chronic hepatitis at 71 years. In the non-NBS group, sweat chloride concentrations using Gibson and Cooke or Exsudose techniques were available in 46 individuals: they were positive (>60 mmol/l) in 14 (30.4%), and borderline (30-59 mmol/l) in 18 (39.1%). In the NBS group, 55/72 children (76.4%) were asymptomatic. Sweat chloride values using Gibson and Cooke or Exsudose techniques, available in 56 children, were >60 mmol/l in 4 (7.1%) and from 30-59 mmol/l in 26 (46.4%). No correlation could be found between sweat chloride values and the phenotype-that is, in particular whether non-NBS patients had isolated CBAVD or a multiorgan disease with pulmonary symptoms.
The probabilities of occurrence of different symptoms with age were determined by Kaplan-Meyer analysis for the 166 (table 2) . Pancreatic insufficiency was found in only three patients; in contrast, respiratory symptoms were quite frequent but generally moderate. Adult onset disseminated bronchiectasis was observed in seven non-NBS patients; Pseudomonas aeruginosa positive sputum cultures were recorded in only one non-NBS patient but six NBS children, three of whom had a positive sweat test (60, 72 and 76 mmol/l). One child, identified through CFNBS, presented with a classical CF phenotype, including recurrent severe pulmonary obstruction and infections, P aeruginosa colonisation and pancreatic insufficiency. She had a positive sweat test and nasal potential difference measurements identical to those found in classical CF. Comprehensive CFTR gene analysis failed to identify a further mutation or large gene rearrangement in cis with R117H;T7 in this child. The low number of patients with the T5 variant precluded any comparison of the phenotypes associated with R117H;T5 and R117H;T7.
Epidemiological data in the French general population
A total of 5245 healthy adults with no family history of CF (10 490 A total of 23 150 newborns with elevated IRT were identified (0.66%). Of these, 52 were compound heterozygous for R117H and F508del (included in the 72 NBS children of the phenotypic study) and 332 homozygous for F508del. All R117H alleles were found on the intron 8 T7 background ( fig 2B) . Consequently, an The measured penetrance of severe CF in childhood in this group was only 0.03% and that of delayed severe CF symptoms in adulthood only 0.06%. The penetrance of CFTR-RD cannot be precisely evaluated because, despite an exhaustive record of cases by the French CF Laboratory Network, a number of patients with mild pulmonary symptoms, pancreatitis or CBAVD may not be tested for CFTR mutations or may ignore their condition throughout their life. The difference in sex ratio in non-NBS individuals (males/ females = 8.3) versus NBS individuals (males/females = 0.95) is compatible with CBAVD being the principal reason for referral in the non-NBS group and supports a very low disease penetrance in women. Beside the single case of classical CF, 13 other NBS children had symptoms that were not specific for CF, mostly bronchial hyperreactivity and nasopharyngeal symptoms. P aeruginosa was found in oropharyngeal cultures in six NBS children (12%), of whom three had positive sweat tests, but whether this is predictive of susceptibility to P aeruginosa infection or colonisation is unclear. In fact, this figure is surprisingly very similar to that of 13% NBS infants with true CF found with P aeruginosa positive oropharyngeal cultures by Armstrong et al. 28 Overall, clinical data in NBS children should be taken with caution, except the CF case, because of the very limited followup. Data from prospective regular follow-up of these children should improve the diagnostic classification of this cohort.
In other respects, because of a lack of correlation between sweat chloride values and the phenotype, it would be interesting to determine whether other physiological tests, such as nasal potential difference measurements, could be more accurate, especially in NBS children, 29 30 in order to identify those who are prone to develop lung disease requiring regular clinical assessments and treatment.
Phenotypic variability is not fully explained by the IVS8 poly(T) variation
The very low frequency of R117H;T5 in our population (but not T5 in isolation) 31 has precluded any correlation between phenotype and the poly(T) variation in cis with R117H. The presence in our study of a severe CF case associated with R117H;T7 and the previously described overlap between patients carrying R117H;T5 and R117H;T7 show that the commonly cited correlation between phenotype and the poly(T) variant in cis with R117H has limitations. 16 18-20 32 However, as R117H;T5 seems to be more frequent in Australian and UK populations and has been associated with a more severe phenotype than R117H;T7, 15 16 determination of the poly(T) variant may still be recommended whenever R117H is detected and R117H;T5 cautiously be considered as a mild CF mutation. Interestingly, five of the seven cases with R117H;T5 originated from Normandy, a north-western area of France which may have common ancestry with the UK.
To what extent does CFNBS detect newborns with R117H? 
Implications for CFNBS and genetic counselling
The pertinence of including R117H and mild CF mutations in CFNBS mutation panels has been debated because of the consequences of making a genetic diagnosis of CF in newborns who might not become symptomatic for years, if at all. 16 arguments in favour of removing R117H from CFNBS mutation panels. However, as withdrawal of R117H would lead to further CFTR testing in NBS children with abnormal neonatal IRT and a positive or borderline sweat test, inclusion of R117H in a second-step panel would be a good compromise. With regard to diagnosis and genetic counselling, R117H;T7 should be considered principally as a CFTR-RD associated mutation with reduced penetrance. This is of critical importance, as CFNBS is being implemented in an increasing number of countries. 26 36 37 As a result, it does not seem justified to automatically offer prenatal diagnosis to the parents of asymptomatic NBS children and cascade screening to their healthy relatives. Moreover, removal of R117H from CF mutation panels used for carrier screening should be considered, as healthy carriers of R117H could wrongly be considered CF carriers and prenatal diagnosis be improperly performed. Finally, this study highlights the need to assess the real impact of so-called disease mutations carefully before including them in screening programmes, either for newborn or carrier screening programmes. 
